Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Capricor Therapeutics (CAPR) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to 0.73%.

  • Capricor Therapeutics' Return on Capital Employed rose 700.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.45% for FY2024, which is 5900.0% up from last year.
  • Capricor Therapeutics' Return on Capital Employed amounted to 0.73% in Q3 2025, which was up 700.0% from 0.52% recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Return on Capital Employed high stood at 0.38% for Q4 2024, and its period low was 3.57% during Q3 2023.
  • Its 5-year average for Return on Capital Employed is 1.09%, with a median of 0.77% in 2024.
  • As far as peak fluctuations go, Capricor Therapeutics' Return on Capital Employed plummeted by -28900bps in 2023, and later soared by 27700bps in 2024.
  • Capricor Therapeutics' Return on Capital Employed (Quarter) stood at 0.55% in 2021, then crashed by -61bps to 0.89% in 2022, then plummeted by -63bps to 1.44% in 2023, then surged by 73bps to 0.38% in 2024, then plummeted by -91bps to 0.73% in 2025.
  • Its Return on Capital Employed stands at 0.73% for Q3 2025, versus 0.52% for Q2 2025 and 0.38% for Q4 2024.